Hytrin

Terazosin, the active ingredient in Hytrin, is an alpha‑1 adrenergic blocker presented as a tablet for oral use. It is employed to lower elevated blood pressure and to relieve urinary obstruction associated with benign prostatic hyperplasia in adult patients. It works by selectively blocking post‑synaptic α1‑adrenergic receptors, leading to vasodilation and reduced smooth‑muscle tone in the prostate and bladder neck.

GNH USA supplies Hytrin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent product quality through rigorous manufacturing oversight and regulatory compliance.

Hytrin is an alpha‑1 adrenergic blocker used in cardiovascular and urological conditions.

Hypertension: reduces systemic vascular resistance to help control blood pressure. Benign prostatic hyperplasia (BPH): relaxes prostate and bladder neck smooth muscle, improving urinary flow and reducing obstruction. Male lower urinary tract symptoms due to BPH: alleviates urgency, frequency and nocturia associated with prostate enlargement.

Common Side Effects: - Dizziness or light‑headedness, especially when standing quickly. - Headache. - Fatigue or general weakness. - Nasal congestion or a runny nose.

Serious or Rare Side Effects: - Syncope or fainting episodes. - Severe hypotension leading to shock. - Allergic reactions such as rash, angioedema or bronchospasm. - Priapism (prolonged painful erection).

Before initiating therapy, consider the following precautions: - Blood pressure monitoring: obtain baseline readings and re‑check after dose changes. - Dose titration: start with a low dose and increase gradually to minimise orthostatic effects. - Avoid abrupt discontinuation: sudden stop may cause rebound hypertension. - Hepatic impairment: impaired metabolism may require dose adjustment. - Pregnancy category B: use only when the potential benefit justifies the potential risk. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Terazosin may interact with several drug classes.

Major Interactions (Avoid): - Potassium‑sparing diuretics (e.g., spironolactone): additive hypotensive effect. - Other α‑blockers (e.g., prazosin, doxazosin): risk of profound blood pressure drop. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increased plasma concentrations.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): reduced therapeutic effect. - NSAIDs: may blunt antihypertensive response. - Beta‑blockers: can mask reflex tachycardia caused by vasodilation.